International Society for Stem Cell Application Presents International Certification in Cellular Therapies Training in Seoul, Korea

Event Announcement

The International Society for Stem Cell Application (ISSCA) proudly announces the upcoming International Certification in Cellular Therapies Training, scheduled to be held in Seoul, Korea, from May 3rd to May 5th, 2024. Sponsored by Global Stem Cells Group, N-BIOTEK Group, Yonsei IMI Stem Clinic, and Regen IC, this training program stands as a pivotal event in the realm of regenerative medicine education.

Training Schedule and Highlights

Commencing on May 3rd with the theoretical component, the training will seamlessly transition into two days of immersive hands-on sessions on May 4th and May 5th at the Yonsei IMI Stem Clinic’s Stem Cell Center. Under the overarching theme of advancing regenerative medicine, the certification training will encompass a broad spectrum of topics, including bone marrow stem cell training and adipose-derived stem cell training, featuring live demonstration therapies and interactive practices. A notable feature of the event includes a Certificate of Completion Ceremony, acknowledging the accomplishments of participants.

Expert Panel Discussions

Esteemed physicians and researchers will lead panel discussions, delving into the latest advancements in regenerative medicine. Key topics to be explored encompass molecular biology, treatment modalities in surgical and cosmetic applications, and groundbreaking technological innovations propelling the field forward.

Unveiling Cutting-Edge Technologies

A significant highlight of the certification training will be the unveiling of cutting-edge technologies in regenerative medicine and cellular therapies. Attendees will have the unique opportunity to witness live demonstrations of Cellgenic bone marrow kits, which have showcased remarkable efficacy in augmenting stem and progenitor cell concentrations in bone marrow aspiration compared to conventional needles. Overcoming limitations associated with traditional needles, such as restricted flow and impurities in aspirated marrow, these kits represent a monumental leap forward in the field.

Statements from Key Figures

Benito Novas, founder of Global Stem Cells Group and Head of Public Relations of ISSCA, expressed, “Through this training and hands-on demonstrations, we aim to further propel the field towards new frontiers of innovation and clinical application.”

Dr. Daeyong Kim, former President, stated, “I am pleased to host this training in Korea, facilitating opportunities for local physicians to advance their expertise in regenerative medicine, thus expanding access to its benefits for our community.”

Dr. Salih Yildirim, the new President, conveyed his enthusiasm, saying, “It is with great pleasure that I return to Korea. Presently, we are organizing several exceptional events, with Korea being a prominent destination among them. We anticipate announcing further initiatives in the near future.”

About ISSCA

The International Society for Stem Cell Application (ISSCA) is a global network of regenerative medicine practitioners dedicated to advancing the field of stem cell therapy through education, research, and advocacy. With chapters spanning across the globe, ISSCA serves as a platform for collaboration and knowledge exchange among professionals in the regenerative medicine community.

About Global Stem Cells Group

The Global Stem Cell Group is a family of several companies focused on stem cell medicine and research. The company uses its network to bring leadership in regenerative medicine training, research, and patient applications. GSCG’s mission is to allow physicians to present the benefits of stem cell medicine to patients worldwide. The company also partners with policymakers, educators, and regulators to promote regenerative medicine.

Global Stem Cells Group is a publicly traded company operating under the symbol MSSV. https://finance.yahoo.com/quote/mssv/

To learn more about Global Stem Cells Group, Inc.’s companies, visit our website www.stemcellsgroup.com or call +1 305 560 5331.

Safe Harbor Statement

Statements in this news release may be “forward-looking statements.” Forward-looking statements include, but are not limited to, statements that express our intentions, beliefs, expectations, strategies, predictions, or any other information relating to our future activities or other future events or conditions. These statements are based on current expectations, estimates, and projections about our business based partly on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties, and assumptions that are difficult to predict. Therefore, actual outcomes and results may and are likely to differ materially from what is expressed or forecasted in forward-looking statements due to numerous factors. Any forward-looking statements speak only as of the date of this news release, and The Global Stem Cells Group undertakes no obligation to update any forward-looking statement to reflect events or circumstances after the date of this news release. This press release does not constitute a public offer of any securities for sale. Any securities offered privately will not be or have not been registered under the Act and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements.

ISSCA Announces Specialized Certification in Advanced Bio-Stimulation

Introduction to the Certification Program

Miami, Florida – The International Society for Stem Cell Application (ISSCA), a distinguished division of the Global Stem Cells Group (GSCG), is pleased to unveil a groundbreaking specialized certification program in Advanced Bio-Stimulation, encompassing Exosomes, Autologous Fibroblasts, Autologous, and Allogeneic Stem

Cells. The program is scheduled to take place in the beautiful city of Cancun, Mexico, on May 10th and 11th, 2024, featuring a comprehensive theoretical session on the first day and hands-on practical training on the second day.

Esteemed Faculty and Keynote Speakers

Joining the esteemed faculty is Dr. Andrea Lapeire, a renowned Argentine doctor with extensive expertise in regenerative medicine and aesthetics. With over eight years of dedicated service within the ISSCA organization, Dr. Lapeire has been instrumental in enriching our symposiums and serving as an instructor in certification courses held in Cancun and Buenos Aires. Dr. Lapeire will spearhead this new program focusing on autologous fibroblasts and advanced bio-stimulation.

Program Curriculum and Key Topics

The Advanced Bio-Stimulation program will delve into a myriad of essential topics, equipping participants with a profound understanding of the latest advancements in regenerative medicine. Some key areas of focus include:

• Regenerative, Reversive, and Preventive Aesthetic Combination
• Theories of Aging
• Cutaneous Modifications in Aging
• Preventive and Reversive Tools: Differentiation
• Regenerative Therapies and their Importance in Health and Aesthetics
• Definition of Bio-Stimulation
• Mechanical, Physical, and Chemical Bio-Stimulants
• Next Generation of Biological Bio-Stimulants
• Collagenesis
• Local and Systemic Fibroblastic Stimulants
• Physical Stimulants: Various Esthetically Significant Technologies
• Photobiomodulation
• Mechanical Stimulants: Biopuncture, Homeosineathria
• PDO Threads: Fundamentals, Bio-Stimulating Techniques, Combined Technique Management
• Protocols: Facial and Body
• Chemical Stimulants: Skin Booster, Mesotherapy, Next Generation
• Slow-Release Hyaluronic Acid: Combination with Bio-Peptides and Amino Acids
• Biological Stimulants: Homeopathized, Peptides, PRP, and Growth Factors
• Regenerative Effect Stimulants: Exosomes, Autologous Fibroblasts, Autologous and Allogeneic Stem Cells in Anti-Aging and Pro-Youth Applications
• Technique Differences, Expectations from Each, Choosing the Ideal for Each Patient, Combining for Result Synergy
• Systemic Stimulants: Orthomolecular, Serum Therapy, Micronutrition, Homeopathized

Theoretical and Practical Training Sessions

The theoretical segment of the program will occur on May 10th, providing participants with a robust knowledge foundation to leverage during the practical sessions. The hands-on training will be conducted at the prestigious Cellular Hope Institute facility on May 11th, enabling participants to apply their theoretical insights in a clinical setting under the guidance of seasoned instructors.

ISSCA’s Commitment to Excellence

Benito Novas, Founder of Global Stem Cells Group and Head of Public Relations for the International Society for Stem Cell Application, expressed his enthusiasm, stating, “We are thrilled to introduce this innovative course at ISSCA. We are committed to remaining at the vanguard of medical advancements, offering unparalleled education and training in regenerative medicine and cell therapies to enable professionals to deliver the utmost quality care to their patients.”

Benefits for Medical Professionals

Participation in these specialized programs is expected to give medical professionals access to cutting-edge research, technological innovations, and clinical protocols, ensuring they are aptly equipped to meet the evolving demands of the regenerative medicine industry. Additionally, ISSCA’s Specializations in Regenerative Medicine and Cell Therapies provide practitioners with an avenue to elevate their clinical practice and enhance patient outcomes through advanced, evidence-based therapies.

Contact Information for Registration

For registration and further information, please contact:

• Email: info@stemcellsgroup.com
• Phone: +1305 560 5337

About ISSCA

The International Society for Stem Cell Application (ISSCA) is a multidisciplinary community of scientists and physicians who aspire to treat diseases and lessen human suffering through advances in science, technology, and the practice of regenerative medicine. ISSCA serves its members through advancements made in the specialty of regenerative medicine. The mission of ISSCA is to establish itself as a global leader in regenerative medicine certification, education, research, and training. ISSCA provides certification training in cities worldwide because it recognizes the importance of standards and certifications in regenerative medicine as a medical specialty. To help more people, both locally and globally, as the demand for more doctors interested in and comfortable with regenerative medicine surges. ISSCA’s mission is to advance quality and uniformity in regenerative medicine worldwide.

About Global Stem Cells Group

The Global Stem Cell Group is a family of several companies focused on stem cell medicine and research. The company uses its network to bring leadership in regenerative medicine training, research, and patient applications. GSCG’s mission is to allow physicians to present the benefits of stem cell medicine to patients worldwide. The company also partners with policymakers, educators, and regulators to promote regenerative medicine. Global Stem Cells Group is a publicly traded company operating under the symbol MSSV. Learn more about Global Stem Cells Group, Inc.’s companies by visiting our website or calling +1 305 560 5331.

Safe Harbor Statement

Statements in this news release may be “forward-looking statements”. Forward-looking statements include, but are not limited to, statements that express our intentions, beliefs, expectations, strategies, predictions, or any other information relating to our future activities or other future events or conditions. These statements are based on current expectations, estimates, and projections about our business based partly on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties, and assumptions that are difficult to predict. Therefore, actual outcomes and results may and are likely to differ materially from what is expressed or forecasted in forward-looking statements due to numerous factors. Any forward-looking statements speak only as of the date of this news release, and The Global Stem Cells Group undertakes no obligation to update any forward-looking statement to reflect events or circumstances after the date of this news release. This press release does not constitute a public offer of any securities for sale. Any securities offered privately will not be or have not been registered under the Act and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements.

Introduction and Announcement

Miami, Florida – Global Stem Cells Group (GSCG) is delighted to announce the successful registration of its Cellgenic Lyophilized Exosomes line throughout the entire region of the United Arab Emirates (UAE). This significant achievement marks a pivotal moment for both GSCG and the field of regenerative medicine in the UAE, facilitating greater access to advanced therapeutic options for healthcare professionals and patients alike.

Understanding Exosomes and Their Importance

Exosomes, extracellular vesicles secreted by cells, have garnered considerable attention in regenerative medicine due to their ability to carry bioactive molecules that modulate various cellular functions critical for tissue repair and regeneration. The Cellgenic Exosomes, now available to practicing doctors in the United Arab Emirates, represent a cutting-edge advancement in this field.

Advantages of Lyophilized Formulation

The registration of Cellgenic Lyophilized Exosomes in the UAE not only empowers healthcare professionals with a powerful therapeutic tool but also streamlines distribution logistics. Unlike traditional exosome products that require stringent refrigeration during transport, the lyophilized formulation can be shipped and stored at ambient temperatures, enhancing accessibility even in regions with challenging infrastructure.

Statements from Leadership

Benito Novas, Founder of the Global Stem Cells Group, expressed his enthusiasm, stating, “With the registration of this groundbreaking exosome product, Global Stem Cells Group reaffirms its commitment to advancing regenerative medicine in the region. We are dedicated to providing healthcare professionals with innovative solutions that can transform patient care and outcomes.”

Dave Christensen, CEO of Global Stem Cells Group, echoed these sentiments, emphasizing the significance of this achievement in expanding the reach of regenerative medicine. “The registration of Cellgenic Lyophilized Exosomes in the UAE represents a significant milestone in our mission to commercialize access to cutting-edge therapies worldwide. We are proud to contribute to the advancement of healthcare in this region and beyond,” he remarked.

GSCG’s Continued Growth and Innovation

Global Stem Cells Group continues to demonstrate rapid growth and innovation, with a global network of offices and a steadfast commitment to driving progress in regenerative medicine. The registration of Cellgenic Lyophilized Exosomes in the UAE further solidifies GSCG’s position as a leader in the field, poised to deliver transformative solutions to patients worldwide.

About Cellgenic

Cellgenic is a distinguished brand renowned for its cellular products and kits featuring the latest advancements in regenerative medicine, including Exosomes, Collagenase, PRP, Wharton’s jelly mesenchymal cells, and more. Committed to excellence in research and development, Cellgenic strives to provide healthcare professionals with cutting-edge technologies of the highest quality to enhance patient care and outcomes.

The Global Stem Cell Group is a family of several companies focused on stem cell medicine and research. The company uses its network to bring leadership in regenerative medicine training, research, and patient applications.

About Global Stem Cells Group

GSCG’s mission is to allow physicians to present the benefits of stem cell medicine to patients worldwide. The company also partners with policymakers, educators, and regulators to promote regenerative medicine.

Global Stem Cells Group is a publicly traded company operating under the symbol MSSV. Learn more about Global Stem Cells Group, Inc.’s companies by visiting our website or calling +1 305 560 5331.

Safe Harbor Statement

Statements in this news release may be “forward-looking statements”. Forward-looking statements include, but are not limited to, statements that express our intentions, beliefs, expectations, strategies, predictions, or any other information relating to our future activities or other future events or conditions. These statements are based on current expectations, estimates, and projections about our business based partly on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties, and assumptions that are difficult to predict. Therefore, actual outcomes and results may and are likely to differ materially from what is expressed or forecasted in forward-looking statements due to numerous factors. Any forward-looking statements speak only as of the date of this news release, and The Global Stem Cells Group undertakes no obligation to update any forward-looking statement to reflect events or circumstances after the date of this news release. This press release does not constitute a public offer of any securities for sale. Any securities offered privately will not be or have not been registered under the Act and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements.

Conference Announcement

MIAMI, Florida – January 29, 2024 – The International Society for Stem Cell Application (ISSCA), a globally recognized leader in regenerative medicine, is delighted to announce its forthcoming regenerative medicine conference in Termez city, Republic of Uzbekistan. The theoretical conference is scheduled to take place on March 4-5, 2024, at the conference hall of the International Research Center Imam Termeziy.

Strategic Partnership

ISSCA has established a strategic partnership with the Ministry of Health of the Republic of Uzbekistan, specifically the Termez branch of Tashkent Medical Academy (Ozbekiston Respublikasi Sogliqni Saqlash Vazirligi), to organize this impactful event. This collaboration exemplifies the shared commitment of ISSCA and the Ministry of Health to advancing healthcare through the dissemination of knowledge in the field of regenerative medicine in the region.

Conference Objectives

The primary objective of the conference is to bring together experts from diverse backgrounds in regenerative medicine, fostering collaboration between science and practice. Distinguished foreign scientists specializing in regenerative medicine, cell therapy applications in degenerative diseases, transplantation, traumatology, dermatology, neuroimmune diseases, and rehabilitation will be in attendance.

Key Focus Areas of the Conference Program

A panel of esteemed experts on stem cells and regenerative medicine will feature at the conference. They will conduct a two-day rigorous research-based discussion on vital topics covering stem cells and regenerative medicine. World-class medical experts in regenerative medicine will share their skills and experience during the theoretical session. The conference will feature esteemed speakers from Turkey, Uzbekistan, and the USA. The conference will focus on a wide range of topics, including:

• Regenerative medicine – the need for knowledge in various fields of medicine
• Exosomes/Extracellular Vesicles
• Mesenchymal stem/stromal cells
• Hematopoietic stem/progenitor cells and engineering
• Gene editing/Gene therapy
• Immunotherapy (CAR-Ts, T Reg, NK cells, etc.)
• Tissue engineering
• Embryonic, organ, and other tissue-specific stem cells
• Application of biomedical cell products in organ and tissue transplantation
• Immunologic aspects of cell therapy for human diseases
• Knowledge in the field of the application of mesenchymal stromal cells in medical practice

ISSCA Leadership’s Insights

Dr. Salih Yildirim

Dr. Salih Yildirim, ISSCA president, expressed his eagerness to share his expertise, stating, “Regenerative medicine is a fast-paced field experiencing exponential growth with ongoing research and product advancements worldwide. We are thrilled to collaborate with the Termez branch of Tashkent Medical Academy to host this conference.”

Benito Novas

Benito Novas, Founder of Global Stem Cells Group and head of public relations at ISSCA, added, “ISSCA’s mission is to share regenerative medicine’s benefits worldwide, supporting patients and physicians in harnessing its power globally.”

A Unique Platform for Knowledge Exchange

The conference expects to be a unique platform for knowledge exchange, collaboration, and advancements in the field of regenerative medicine. ISSCA invites professionals, researchers, and enthusiasts to join this groundbreaking event in the pursuit of enhancing global healthcare through cutting-edge regenerative medicine practices.

For more information, please visit ISSCA Conference – Tashkent, March 2024.

Final Words About the Conference

Regenerative medicine is rapidly growing with continuous explorations revealing new protocols and products. The conference aims to keep participants updated with the industry’s most recent changes and advancements, empowering them to explore more opportunities and be part of a valuable stem cell community.

Contact Information

Learn more about ISSCA and advancements in stem cell therapy by visiting our website or emailing us at info@stemcellsgroup.com.

About the Termiz Branch of the Tashkent Medical Academy

Established in 2018, the Termiz branch of the Tashkent Medical Academy aims to produce highly skilled medical professionals meeting global standards. Committed to academic excellence, the branch offers opportunities for teachers to obtain scientific degrees through research, conducting doctoral dissertations, and anticipates a progressive increase in research activities, solidifying its role in shaping Uzbekistan’s healthcare future.

About ISSCA

The International Society for Stem Cell Application (ISSCA) is a multidisciplinary community of scientists and physicians who aspire to treat diseases and lessen human suffering through advances in science, technology, and the practice of regenerative medicine. ISSCA serves its members through advancements made in the specialty of regenerative medicine. The mission of ISSCA is to establish itself as a global leader in regenerative medicine certification, education, research, and training. ISSCA provides certification training in cities worldwide because it recognizes the importance of standards and certifications in regenerative medicine as a medical specialty. To help more people, both locally and globally, as the demand for more doctors interested in and comfortable with regenerative medicine surges. ISSCA’s mission is to advance quality and uniformity in regenerative medicine worldwide.

About Global Stem Cells Group

The Global Stem Cell Group is a family of several companies focused on stem cell medicine and research. The company uses its network to bring leadership in regenerative medicine training, research, and patient applications. GSCG’s mission is to allow physicians to present the benefits of stem cell medicine to patients worldwide. The company also partners with policymakers, educators, and regulators to promote regenerative medicine. Global Stem Cells Group is a publicly traded company operating under the symbol MSSV. Learn more about Global Stem Cells Group, Inc.’s companies by visiting our website or calling +1 305 560 5331.

Safe Harbor Statement

Statements in this news release may be “forward-looking statements.” Forward-looking statements include, but are not limited to, statements that express our intentions, beliefs, expectations, strategies, predictions, or any other information relating to our future activities or other future events or conditions. These statements are based on current expectations, estimates, and projections about our business based partly on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties, and assumptions that are difficult to predict. Therefore, actual outcomes and results may and are likely to differ materially from what is expressed or forecasted in forward-looking statements due to numerous factors. Any forward-looking statements speak only as of the date of this news release, and The Global Stem Cells Group undertakes no obligation to update any forward-looking statement to reflect events or circumstances after the date of this news release. This press release does not constitute a public offer of any securities for sale. Any securities offered privately will not be or have not been registered under the Act and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements.

Introduction

Miami, Florida [01/22/2024] – Global Stem Cells Group, a pioneer in the regenerative medicine sector, has outlined its strategic projections for the year 2024. The company, committed to advancing stem cell research, patient treatments, and physician education, aims to generate over $4 million in top-line revenue through a multifaceted approach within the rapidly expanding stem cell therapy market.

Market Overview

The regenerative medicine market, poised to reach USD 90.13 Billion by 2030, is witnessing unprecedented growth. Recognizing the vast potential of regenerative medicine, Global Stem Cells Group aims to play a pivotal role in shaping the dynamic landscape of this industry.

Business Strategy in 2024

Certified Training Courses for Physicians

Global Stem Cells Group’s educational arm, the International Society for Stem Cells Application (ISSCA), is set to conduct 2 courses every month at various affiliated centers worldwide. These courses aim not only to disseminate cutting-edge knowledge but also to establish new industry standards, enhancing the quality and rigor of training in regenerative medicine.

Milestones and goals for 2024 include global expansion, hosting 3 international congresses, introducing advanced courses on cutting-edge technologies, and establishing permanent courses and workshops at ReGen Networks Clinics.

Manufacturing and Sales of Newest Technology, Supplies, and Equipment

In the sale of cellular therapy products and technologies, Global Stem Cells Group plans to boost global sales by establishing validation departments, integrating new technologies into the Cellgenic product line, and establishing distribution centers in various countries. The goal is to position the company at the forefront of the evolving field of regenerative medicine.

Research and Development of Clinical Protocols

Global Stem Cells Group is committed to pioneering new frontiers in regenerative medicine by developing cutting-edge treatment protocols. The incorporation of innovative technologies reflects the company’s dedication to providing patients and physicians with advanced therapeutic options.

Regenerative Medicine Clinics (Patient Treatment)

Expansion plans in 2024 include the opening of two new treatment centers alongside the continued growth of the existing center in Cancun. These centers are expected to serve as training centers for physicians, research and development hubs, and contribute to top-line revenue through treatment services, physician training programs, research collaborations, and product development.

Membership Network of Regenerative Medicine Practitioners

Global Stem Cells Group aims to expand its ReGen network by opening four new regenerative medicine centers across the globe. The ReGen membership program offers a comprehensive turnkey solution for individuals interested in establishing their own regenerative medicine clinic, contributing to revenue growth.

Turnkey Solutions for Stem Cell Processing Center Installation & Management

In 2024, Global Stem Cells Group envisions a pioneering role in the field of personalized stem cell laboratories, offering bespoke projects tailored to clients’ unique needs and setting new benchmarks in regenerative medicine.

Market Positioning and Recognition

The strategic expansion into these key areas positions Global Stem Cells Group as a global leader in regenerative medicine. The company’s commitment to education, product sales, research, patient services, and strategic partnerships within the stem cell therapy market sets the stage for transformative achievements in 2024.

Through these strategic initiatives, Global Stem Cells Group aims to not only contribute to the continuous advancement of regenerative medicine but also to position itself as a global leader in the industry.

Call to Action

The company invites healthcare professionals, researchers, and stakeholders to join them on this transformative journey as they redefine the future of medical innovation and elevate the standards of regenerative medicine in 2024.

About Global Stem Cells Group

The Global Stem Cell Group is a family of several companies focused on stem cell medicine and research. The company uses its network to bring leadership in regenerative medicine training, research, and patient applications. GSCG’s mission is to allow physicians to present the benefits of stem cell medicine to patients worldwide. The company also partners with policymakers, educators, and regulators to promote regenerative medicine. Global Stem Cells Group is a publicly traded company operating under the symbol MSSV. Learn more about Global Stem Cells Group, Inc.’s companies by visiting our website or calling +1 305 560 5331.

Safe Harbor Statement

Statements in this news release may be “forward-looking statements.” Forward-looking statements include, but are not limited to, statements that express our intentions, beliefs, expectations, strategies, predictions, or any other information relating to our future activities or other future events or conditions. These statements are based on current expectations, estimates, and projections about our business based partly on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties, and assumptions that are difficult to predict. Therefore, actual outcomes and results may and are likely to differ materially from what is expressed or forecasted in forward-looking statements due to numerous factors. Any forward-looking statements speak only as of the date of this news release, and The Global Stem Cells Group undertakes no obligation to update any forward-looking statement to reflect events or circumstances after the date of this news release. This press release does not constitute a public offer of any securities for sale. Any securities offered privately will not be or have not been registered under the Act and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements.

International Society for Stem Cell Application (ISSCA) Announces International Symposium on Regenerative Medicine and Cellular Therapies in Cancún, México

Introduction

Miami, Florida – The International Society for Stem Cell Application (ISSCA), a distinguished division of the Global Stem Cells Group (GSCG), is delighted to unveil its much-anticipated international symposium on Regenerative Medicine and Cellular Therapies. This groundbreaking event is set to take place in the vibrant city of Cancún, México, over three days, from June 14th to 16th, 2024, with one day dedicated to conferences and the subsequent two days featuring hands-on sessions.

A Global Gathering of Scientific Minds

The symposium aims to bring together leading scientists and medical professionals from around the world, providing an unparalleled platform to explore and discuss the latest advancements in regenerative medicine. With elite speakers, including renowned scientists and physicians with extensive experience in the field, attendees are expected to gain unique insights into the cutting-edge clinical applications of stem cell therapies.

Key Highlights of the Symposium

Stay Ahead with the Latest Technologies

Attendees will be at the forefront of breakthrough technologies in regenerative medicine. Learn about the most recent advancements that are reshaping the landscape of healthcare and discover how these technologies may elevate your practice and patient care.

Explore Cutting-Edge Products and Equipment

Gain firsthand insights into the latest products and equipment driving the field of stem cell therapy. From state-of-the-art medical devices to groundbreaking tools, discover innovations that may enhance your clinical practice and contribute to better patient outcomes.

Delve into Tissue Engineering

Tissue engineering is a frontier where science meets medical marvels. Attendees will have the opportunity to delve into the intricacies of tissue engineering, understanding how it is revolutionizing regenerative medicine and paving the way for transformative treatments.

Comprehensive Understanding of Regenerative Medicine

Broaden your understanding of regenerative medicine as a whole. From foundational principles to cutting-edge applications, the symposium provides a comprehensive overview, equipping attendees with the knowledge needed to excel in this rapidly evolving field.

Network with Industry Leaders and Peers

Connect with a diverse and dynamic community of professionals, including doctors, researchers, innovators, and decision-makers. Engage in meaningful conversations, forge collaborations, and build a network that extends beyond the symposium, providing ongoing support and insights.

Acquire Practical Knowledge from Hands-On Training

Beyond theoretical insights, the symposium offers invaluable hands-on training sessions led by ISSCA-certified instructors. Gain practical experience in the aesthetic and clinical applications of stem cell therapy, ensuring you leave with skills ready for immediate implementation.

Navigate Regulatory Challenges

Stay informed on the latest regulatory and ethical considerations in stem cell technology. Navigate the complexities of compliance while gaining insights into how to address challenges in a rapidly evolving regulatory landscape.

Stay Informed on Marketing Trends

Learn about modern technologies that can enhance your marketing efforts in the field of regenerative medicine. Stay ahead of the curve with insights into effective strategies to promote your practice and reach a wider audience.

Conclusion

In short, the ISSCA International Symposium is not just an event; it is an immersive experience that seeks to empower attendees with the knowledge, skills, and connections needed to shape the future of regenerative medicine. Join us in Cancún, México, and be a catalyst for positive change in the medical landscape.

Contact Information

For registration and additional information, please contact:

• Email: info@stemcellsgroup.com
• Phone: +1 305 560 5337

About ISSCA

The International Society for Stem Cell Application (ISSCA) is a multidisciplinary community of scientists and physicians who aspire to treat diseases and lessen human suffering through advances in science, technology, and the practice of regenerative medicine. ISSCA serves its members through advancements made in the specialty of regenerative medicine.

The mission of ISSCA is to establish itself as a global leader in regenerative medicine certification, education, research, and training. ISSCA provides certification training in cities worldwide because it recognizes the importance of standards and certifications in regenerative medicine as a medical specialty. To help more people, both locally and globally, as the demand for more doctors interested in and comfortable with regenerative medicine surges, ISSCA’s mission is to advance quality and uniformity in regenerative medicine worldwide.

About Global Stem Cells Group

The Global Stem Cell Group is a family of several companies focused on stem cell medicine and research. The company uses its network to bring leadership in regenerative medicine training, research, and patient applications. GSCG’s mission is to allow physicians to present the benefits of stem cell medicine to patients worldwide. The company also partners with policymakers, educators, and regulators to promote regenerative medicine.

Global Stem Cells Group is a publicly traded company operating under the symbol MSSV. Learn more about Global Stem Cells Group, Inc.’s companies by visiting our website or calling +1 305 560 5331.

Safe Harbor Statement

Statements in this news release may be “forward-looking statements.” Forward-looking statements include, but are not limited to, statements that express our intentions, beliefs, expectations, strategies, predictions, or any other information relating to our future activities or other future events or conditions. These statements are based on current expectations, estimates, and projections about our business based partly on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties, and assumptions that are difficult to predict. Therefore, actual outcomes and results may and are likely to differ materially from what is expressed or forecasted in forward-looking statements due to numerous factors. Any forward-looking statements speak only as of the date of this news release, and The Global Stem Cells Group undertakes no obligation to update any forward-looking statement to reflect events or circumstances after the date of this news release. This press release does not constitute a public offer of any securities for sale. Any securities offered privately will not be or have not been registered under the Act and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements.